Citius Oncology, Inc. Common Stock
Symbol: CTOR (NASDAQ)
1.92
▲ (0.79%) 0.015
Company Description:
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
Key Stats
- Today's Open: $1.92
- Today's High: $1.93
- Today's Low: $1.825
- Today's Volume: 54.87K
- Yesterday Close: $1.9
- Yesterday High: $1.97
- Yesterday Low: $1.7238
- Yesterday Volume: 231.00K
- Last Min Volume: 96
- Last Min High: $1.914
- Last Min Low: $1.911
- Last Min VWAP: $1.914
Company Profile
- Name: Citius Oncology, Inc. Common Stock
- Website: https://www.citiusonc.com
- Listed Date: 2024-08-13
- Location: CRANFORD, NJ
- Market Status: Active
- CIK Number: 0001851484
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $144.20M
- Round Lot: 100
- Outstanding Shares: 78.37M
- Asset Type: CS
RECENT FILINGS FOR CTOR
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-10 | 424B5 | View |
| 2025-09-04 | EFFECT | View |
| 2025-09-02 | S-3 | View |
| 2025-08-20 | DRS | View |
| 2025-08-18 | 8-K | View |
| 2025-08-18 | 424B3 | View |
| 2025-08-12 | 8-K | View |
| 2025-08-12 | 10-Q | View |
| 2025-08-07 | 4 | View |
| 2025-07-25 | SCHEDULE 13D/A | View |
| 2025-07-18 | 8-K | View |
| 2025-07-17 | 424B4 | View |
| 2025-07-16 | EFFECT | View |
| 2025-07-15 | CORRESP | View |
| 2025-07-14 | S-1/A | View |
| 2025-07-14 | S-1 | View |
| 2025-06-27 | 8-K | View |
| 2025-06-17 | 8-K | View |
| 2025-05-14 | 10-Q | View |
| 2025-05-14 | 8-K | View |
Latest News on CTOR